Free Trial
NASDAQ:TAOX

Synaptogenix Q1 2026 Earnings Report

Synaptogenix logo
$3.81 -0.25 (-6.16%)
Closing price 06/5/2026 04:00 PM Eastern
Extended Trading
$3.82 +0.02 (+0.39%)
As of 06/5/2026 07:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Synaptogenix EPS Results

Actual EPS
$0.43
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Synaptogenix Revenue Results

Actual Revenue
$5.96 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Synaptogenix Announcement Details

Quarter
Q1 2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Synaptogenix Earnings Headlines

I was right about SpaceX
Jeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.tc pixel
TAO Synergies Announces $11 Million Private Placement
See More Synaptogenix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Synaptogenix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Synaptogenix and other key companies, straight to your email.

About Synaptogenix

Synaptogenix (NASDAQ:TAOX) operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.

View Synaptogenix Profile